Everything you need to know about bone cancer — from symptoms and staging to treatment options and life after diagnosis — explained clearly by Dr. Aditya Sarin.
This page is for informational purposes only and does not constitute medical advice, diagnosis or treatment. Every case of bone cancer is different. Please consult Dr Aditya Sarin or a qualified oncologist for evaluation, diagnosis and a treatment plan specific to your condition.
Bone pain that worsens at night, or doesn't improve with rest, deserves evaluation. Schedule an evaluation with Dr. Aditya Sarin today.
Bone cancer starts in the bone itself, where cells begin growing and dividing abnormally. It's important to draw a distinction here. Most cancer found in bone didn't actually start there. It's far more common for cancer to spread to bone from somewhere else, such as the breast, prostate, or lung. That's called metastatic or secondary bone cancer, and it's treated very differently from cancer that genuinely originates in the bone.
This page focuses on primary bone cancer — cancer that starts in the bone tissue itself. It's rare, making up less than 1% of all cancers, but it disproportionately affects children, teenagers, and young adults, which makes early recognition especially important.
Primary bone cancer is not a single disease. The specific type strongly influences who it affects, how it behaves, and how it's treated. Dr. Aditya Sarin evaluates each case individually to confirm the precise diagnosis before deciding on treatment.
The most common type of primary bone cancer, and the most common in children and teenagers. Usually develops in the long bones of the arms and legs.
Starts in cartilage cells. Typically grows more slowly than osteosarcoma and usually appears after age 40.
Can grow and spread quickly, most often affecting the pelvis, chest wall, and long bones.
A rare, slow-growing cancer that develops along the spine or at the base of the skull, requiring highly specialised surgical expertise.
Bone pain is the most common early symptom, and it has a particular pattern worth knowing: it often gets worse at night and doesn't improve with rest, unlike most everyday aches and strains.
Note: Growing pains and sports injuries are far more common than bone cancer, especially in children and teens. Still, pain that persists, worsens, or wakes someone up at night deserves proper evaluation.
The exact cause of most bone cancer isn't known, but a few factors are clearly linked to higher risk.
Osteosarcoma occurs most often during the rapid bone growth of adolescence.
Causes abnormal bone growth and remodelling, raising the risk of osteosarcoma, particularly in older adults.
Radiation treatment for an earlier cancer, especially at a young age, increases risk years later.
Li-Fraumeni syndrome and hereditary retinoblastoma significantly raise the risk of osteosarcoma.
Having a risk factor doesn't mean someone will develop bone cancer, and most people diagnosed have no identifiable risk factor beyond age.
There's no routine population-wide screening test for bone cancer. Early detection depends on recognising persistent bone pain or swelling and following through with proper imaging rather than assuming it's a strain or growing pain.
Often the first imaging test, and frequently how a bone abnormality is first noticed.
Detailed imaging to assess the size of the tumour and whether it has spread beyond the bone.
A tissue sample confirms the diagnosis, ideally performed at a centre experienced in bone sarcoma.
Since bone sarcomas can spread to the lungs, chest imaging is a standard part of the initial workup.
Persistent bone pain that doesn't fit the pattern of a typical strain, especially pain that wakes someone up at night or comes with swelling, deserves an X-ray rather than a wait-and-see approach.
Staging describes how far the cancer has spread and directly shapes the treatment approach. Bone cancer staging combines tumour grade, how aggressive the cells look under a microscope, with tumour size and whether it has spread beyond the bone. This staging guidance is current as of 2026.
Survival statistics are population averages. They describe outcomes across large groups of patients and don't predict what will happen to any individual patient.
Source: Factors Affecting Prognosis and Survival in Extremity Osteosarcoma. The gap between neoadjuvant and upfront surgery outcomes in this study is striking, and underscores how much the specific treatment protocol followed shapes long-term survival.
Treatment depends on the specific type, grade, and stage. Bone cancer is treated by a multidisciplinary team, and Dr. Aditya Sarin coordinates a comprehensive, personalised treatment plan for every patient.
Removes the tumour while preserving the limb, often using a metal implant or bone graft. The preferred approach whenever oncologically safe.
Sometimes still necessary when a tumour is too large or too involved with nerves and blood vessels for limb-salvage surgery to be safe.
A cornerstone of treatment for osteosarcoma and Ewing sarcoma, typically given both before and after surgery.
Chondrosarcoma responds poorly to radiation, but it plays a significant role in Ewing sarcoma, particularly when surgery isn't feasible.
An option for select cases, including denosumab for giant cell tumour of bone, a related but distinct bone tumour.
Physiotherapy and, where needed, prosthetic fitting are a core part of recovery after limb-salvage surgery or amputation.
It's worth being honest here. Core treatment protocols for osteosarcoma have changed relatively little since the 1980s, when the addition of chemotherapy to surgery first transformed survival rates. Most current research effort is focused on the broader sarcoma family, and some of that progress is starting to open doors for bone sarcomas too.
In 2024, the FDA granted accelerated approval to afamitresgene autoleucel, a T-cell receptor engineered cell therapy, for synovial sarcoma, a related soft tissue sarcoma. Full approval followed in 2026, with the treatment shrinking tumours in close to half of patients in the supporting trial, some with lasting responses. This is a soft tissue sarcoma approval rather than a primary bone sarcoma one, but it represents an important proof of concept for cell-based therapy across the sarcoma family, and similar approaches are now being studied in bone sarcomas.
Several current trials are testing whether adding targeted drugs such as cabozantinib to standard chemotherapy can improve outcomes in newly diagnosed and relapsed osteosarcoma, an area worth watching for patients with limited options after standard treatment stops working.
Bone cancer treatment, particularly surgery, affects mobility and daily function in ways that make coordinated rehabilitation an essential part of recovery, not an afterthought.
Structured rehabilitation to rebuild strength and function after limb-salvage surgery or amputation.
Coordination with prosthetics and reconstructive specialists to support long-term mobility and independence.
Emotional support and peer groups for patients and families, particularly valuable given how often this cancer affects children and young adults.
ESMO Board Certified · Harvard Trained · Sir Ganga Ram Hospital, New Delhi
ESMO Board Certified oncologist with advanced training in precision oncology and cancer genomics from Harvard Medical School.
Treatment planned alongside orthopaedic oncology, radiation oncology, and rehabilitation specialists.
Personalised treatment plans, rehabilitation coordination, emotional counselling, and end-to-end support.
High-quality oncology care with insurance assistance, flexible appointment options, and both in-person and remote consultations.
Don't dismiss persistent bone pain as just a strain, especially in a growing teenager. If you've noticed persistent bone pain, swelling, or simply want expert guidance following an unusual fracture, speak with Dr. Aditya Sarin — a trusted bone cancer specialist in New Delhi.
📅 Book Your Consultation